The following pages link to Annals of Oncology (Q326122):
Displaying 50 items.
- European Society for Medical Oncology (Q5413188) (← links)
- Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra (Q24289204) (← links)
- Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses (Q24289205) (← links)
- Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials (Q24599547) (← links)
- The epithelial-mesenchymal transition (EMT) phenomenon (Q24600898) (← links)
- European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document (Q24644710) (← links)
- Prevalence of undertreatment in cancer pain. A review of published literature (Q24646347) (← links)
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 (Q24657145) (← links)
- Crizotinib resistance: implications for therapeutic strategies (Q26738381) (← links)
- The role of the ALK receptor in cancer biology (Q26738384) (← links)
- Crizotinib: from discovery to accelerated development to front-line treatment (Q26738385) (← links)
- ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology (Q26738387) (← links)
- Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? (Q26738390) (← links)
- The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy (Q26744087) (← links)
- Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective (Q26744089) (← links)
- The promise of immunotherapy in head and neck squamous cell carcinoma (Q26744433) (← links)
- Cervical esophageal cancer: a gap in cancer knowledge (Q26749536) (← links)
- Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis (Q26773464) (← links)
- Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics (Q26776391) (← links)
- Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes (Q26778754) (← links)
- Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer (Q26782494) (← links)
- Muscle dysfunction in cancer patients (Q26822365) (← links)
- State of the art of surgery in advanced epithelial ovarian cancer (Q26822788) (← links)
- Breast cancer risk in BRCA1 mutation carriers: insight from mouse models (Q26823062) (← links)
- Sorafenib: from literature to clinical practice (Q26826933) (← links)
- Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature (Q26827698) (← links)
- Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies (Q26828925) (← links)
- Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer (Q26829939) (← links)
- The contribution of molecular epidemiology to the identification of human carcinogens: current status and future perspectives (Q26830046) (← links)
- The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck (Q26830495) (← links)
- Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review (Q26850736) (← links)
- Targeting triple-negative breast cancer: optimising therapeutic outcomes (Q26850892) (← links)
- Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature (Q26851579) (← links)
- Dietary patterns and gastric cancer risk: a systematic review and meta-analysis (Q26851692) (← links)
- Clinical biomarkers of response in advanced renal cell carcinoma (Q26852564) (← links)
- Origin and molecular pathogenesis of ovarian high-grade serous carcinoma (Q26852698) (← links)
- The impact of the process of clinical research on health service outcomes (Q26858784) (← links)
- Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease (Q26859466) (← links)
- A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment (Q26862558) (← links)
- Imaging bone metastases in breast cancer: evidence on comparative test accuracy (Q26862731) (← links)
- Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer (Q26865075) (← links)
- High-quality care for all children with cancer (Q26992044) (← links)
- PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis (Q26992267) (← links)
- Targeted therapies and the treatment of non-clear cell renal cell carcinoma (Q26995391) (← links)
- Designs of drug-combination phase I trials in oncology: a systematic review of the literature (Q26996348) (← links)
- Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies (Q26996384) (← links)
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids (Q26996521) (← links)
- The sequential use of endocrine treatment for advanced breast cancer: where are we? (Q26997396) (← links)
- Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials (Q26998248) (← links)
- Quality assurance in the treatment of colorectal cancer: the EURECCA initiative (Q26998562) (← links)